The point company has not been onto PR has made it difficult for continuous SP rise. Last quarterly should have news of AU enteric site open, FDA application, new partner overseas and winter flu testing sales, due in 2 weeks time. Both FY22 report and FY23 outlook should be bright and take SP upwards from here.
GSS Price at posting:
$1.00 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)